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Abstract 43 
Human glioblastomas may be hierarchically organized. Within this hierarchy 44 
glioblastoma-initiating cells (GIC) have been proposed to be more resistant to 45 
radiochemotherapy and responsible for recurrence. Here, established stem cell 46 
markers and stem cell attributed characteristics such as self-renewal capacity and 47 
tumorigenicity have been profiled in primary glioblastoma cultures to predict 48 
radiosensitivity. 49 
Furthermore, the sensitivity to radiotherapy of different subpopulations within a single 50 
primary glioblastoma culture was analyzed by a flow cytometric approach using 51 
Nestin, SRY (sex determining region Y)-box 2 (SOX2) and glial fibrillary acidic protein 52 
(GFAP). 53 
The protein expression of Nestin and SOX2 as well as the mRNA levels of Musashi1, 54 
L1CAM, CD133, Nestin and PLAGL2 inversely correlated with radioresistance in 55 
regard to the clonogenic potential. Only CD44 protein expression correlated 56 
positively with radioresistance. In terms of proliferation, Nestin protein expression 57 
and Musashi1, PLAGL2 and CD133 mRNA levels inversely correlated with 58 
radioresistance. Higher expression of stem cell markers does not correlate with 59 
resistance to radiochemotherapy in a TCGA (the cancer genome atlas) glioblastoma 60 
collective. SOX2 expressing subpopulations exist within single primary glioblastoma 61 
cultures. These subpopulations form predominantly the proliferative pool of the 62 
primary cultures and are sensitive to irradiation.  63 
Thus, profiling of established stem cell markers revealed a surprising result. Except 64 
CD44, the tested stem cell markers showed an inverse correlation between 65 
expression and radioresistance.  66 
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Introduction 70 
For many years, glioblastoma, the most frequent and aggressive primary brain tumor 71 
in adults, has been regarded as a clonal malignancy and was modelled in vitro by 72 
established glioma cell lines kept in serum-containing medium (SCM). Evidence 73 
emerged that primary glioma cell cultures may better reflect the genetic and biologic 74 
features of glioblastoma (Bjerkvig et al. 2005). At present, the search for glioblastoma 75 
subpopulations that are distinct from the main tumor and responsible for tumor 76 
initiation and progression as well as resistance to therapy is ongoing. Such cells are 77 
usually termed cancer stem cells (CSC) or glioblastoma-initiating cells (GIC), 78 
reflecting rather a concept than unequivocal evidence and only a few examples exist 79 
for these cells being a therapeutic target (Zhu et al. 2014). GICs are defined by their 80 
properties to self-renew, to express stem cell markers and most importantly to be 81 
highly tumorigenic and able to recapitulate a phenocopy of the tumor of origin in 82 
immunocompromized mice when transplanted orthotopically in low cell numbers.  83 
We aimed at profiling different GIC cultures and different subgroups within single GIC 84 
cultures to evaluate how the various stem cell markers and techniques to detect stem 85 
cells, which are the product of an intense research over the last years (Bao et al. 86 
2006;Bao et al. 2008;Fukaya et al. 2010;Rasper et al. 2010;Singh et al. 2003;Suva et 87 
al. 2009;Thon et al. 2010;Zheng et al. 2010) correlate with resistance to radiotherapy.  88 
Furthermore, we tried to detect the stem cell subpopulation within single GIC 89 
cultures, to analyse whether they form the radioresistant pool of the GIC culture. 90 
The analysis was done on different levels. The clonogenic potential of the different 91 
GIC cultures was estimated by the limiting dilution assay (LDA), proliferation was 92 
measured by BrdU- or EdU-uptake. Radioresistance was assessed by the relative 93 
decline in proliferation and clonogenic potential after irradiation with 4 Gy. These 94 
results were correlated with the protein expression of the stem cell markers CD133, 95 
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CD15, CD44, Nestin and SOX2 measured by flow cytometry as well as the mRNA 96 
expression levels of various stem cell markers.   97 
To confirm our data the same markers were analyzed in a radiochemotherapy-98 
treated TCGA collective of glioblastoma patients. Finally, we evaluated with the help 99 
of flow cytometry whether stem-cell subpopulations exist within a single GIC culture 100 
which behave differentially from the non-stem cells. Exemplarily, the in vitro data 101 
were verified in vivo by orthotopical xenotranplantation of glioma initiating cells in 102 
nude mice. 103 
 104 
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Material and methods 105 
Cell culture 106 
Tumor samples were obtained from adult patients diagnosed with glioblastoma after 107 
informed consent. Glioma-initiating cell cultures (GIC cultures) were established from 108 
freshly dissected tumor tissue with a success rate of 1/4 tumors. Tumor and 109 
neurosphere cultures were cultured as described (Hemmati et al. 2003). Cells were 110 
seeded in neural sphere cell medium (NSCM) containing DMEM:F12 medium 111 
enriched with B27 supplement, basic fibroblast growth factor (bFGF) (20 ng/ml), 112 
epidermal growth factor (EGF) (20 ng/ml) and leukemia inhibitory factor (LIF) (20 113 
ng/ml) (Hemmati et al. 2003). To propagate cells in culture they were split 114 
mechanically. For all the experiments requiring a single cell suspension spheres 115 
were split with accutase (PromoCell, Heidelberg, Germanny). To obtain adherent, 116 
differentiated cells, tumor cells were cultured in SCM medium (10% FCS, fetal calf 117 
serum) on poly-L-lysine-coated tissue flasks for 15 days. Alternatively, differentiation 118 
was induced by withdrawal of EGF and bFGF, culture on a poly-L-lysine coated 119 
surface and supplementation of recombinant bone morphogenetic protein 2, BMP-2, 120 
(10-50 ng/ml) or CNTF (50 ng/ml), (R&D systems, Minneapolis, MN, USA) with and 121 
without 5-Azacytidin (3 µM) (AXXORA, Lausen Switzerland) 3 days prior to fixation 122 
and subsequently analyzed by immunofluorescence microscopy and flow cytometry 123 
(Lee et al. 2008). Glioblastoma origin was confirmed by comparative genomic 124 
hybridization (Toedt et al. 2011) indicating typical genomic alterations on 125 
chromosomes 7q, 10p, 17q (Holland et al. 2010). A subset of the GIC cultures (WJ 126 
and PJ) was analyzed by Illumina Human Methylation 450 array performed from DNA 127 
extracted from cell lines. The array data was used to calculate a low-resolution copy 128 
number profile as previously described (Sturm et al. 2012). 129 
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Human astrocytes (ScienCell Research Laboratories, Carlsbad, CA, USA) were kept 130 
in astrocyte medium (ScienCell Research). 131 
 132 
Quantitative Real-Time PCR (qRT-PCR) 133 
Total RNA was extracted using a RNA purification system (Qiagen, Hilden, Germany) 134 
and treated with RNase-free DNase I to remove genomic DNA (Roche, Mannheim, 135 
Germany). cDNA was prepared from 5 µg of total RNA using the Superscript RNase 136 
H–Reverse Transcriptase (Invitrogen, Karlsruhe, Germany) and random hexamers 137 
(Sigma-Aldrich, Taufkirchen, Germany). For qRT-PCR, gene expression was 138 
measured in an ABI Prism 7000 Sequence Detection System (Applied Biosystems, 139 
Foster City, CA, USA) with SYBR Green Master Mix (Eurogentec, Cologne, 140 
Germany) and primers at optimized concentrations (Opitz et al. 2009). Primers 141 
(Sigma-Aldrich, Taufkirchen, Germany) were selected to span exon–exon junctions if 142 
possible. Standard curves were generated for each gene and the amplification was 143 
90–100% efficient. Relative quantification of gene expression was determined by 144 
comparison of threshold values. All results were normalized to GAPDH. The 145 
sequences for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 146 
(GAPDH) and the genes evaluated were as follows:  147 
GAPDH_fw:   CTCTCTGCTCCTCCTGTTCGAC 148 
GAPDH_rev:   TGAGCGATGTGGCTCGGCT 149 
CD133_fw:   CATCCACAGATGCTCCTAAGGC 150 
CD133_rev:   AAGAGAATGCCAATGGGTCCA 151 
ALDH1_fw:   TGCTTCCGAGAGGGGGCGAC 152 
ALDH1_rev:   TCCATTGTCGCCAGCAGCAGAC 153 
ABCG2_fw:   ACGAACGGATTAACAGGGTCA 154 
ABCG2_rev:   CTCCAGACACACCACGGAT 155 
 8
L1CAM_fw:   GGTCCCTGGAGAGTGACAACGAGGA 156 
L1CAM_rev:   GGCCCCTGAGCTGTCATTGCC 157 
Musashi1_fw:  GGGAGGTGAAGGAGTGTCTG 158 
Musashi1_rev:  CTGGTCCATGAAAGTGACGAA 159 
EZH2_fw:   GCTCAAGAGGTTCAGACGAG 160 
EZH2_rev:   GCTGTTTCCATTCTTGGTTTAAG 161 
PLAGL2_fw:   GAGTCAAGTGAAGTGCCAATGT 162 
PLAGL_rev:   TGAGGGCAGCTATATGGTCTC 163 
Nestin_fw:   GGTGGCCACGTACAGGACCCT  164 
Nestin_rev:   AGATCCAAGACGCCGGCCCT 165 
 166 
Clonogenic capacity and sensitivity towards radiotherapy 167 
To assess the clonogenic capacity limiting dilution assay, LDA, was performed as 168 
described (Eirew et al. 2010). Shortly, cells were dissociated with accutase. 169 
Afterwards, 24 wells of a 96-well microwell plate were each plated with 300, 50, 8 170 
and 1 cells in 0.2 ml of NSCM. After three weeks microwell plates were analyzed for 171 
wells showing clones and clonal frequency as well as the standard error of the mean 172 
(SEM) was calculated with L-Calc free online software (STEMCELL Technologies). 173 
Stem cell frequency was expressed by 1 / the minimum amount of cells necessary to 174 
form a colony. To evaluate the radioresistance LDA was also performed after 175 
irradiation at 4 Gray (Gy).  176 
Experiments to assess differential radiosensitivity were also performed within 177 
subfractions of GIC cultures kept in NSCM and analyzed by flow cytometry. 178 
Proliferation assessed by bromodeoxyuridine, BrdU, incorporation and cell cycle 179 
distribution (DNA content) of different GIC subfractions were measured 72 h after 180 
irradiation at 4 and 8 Gy.  181 
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 182 
Immunocytochemistry and flow cytometry  183 
Immunocytochemistry of neurosphere cultures was performed as described 184 
(Geschwind et al. 2001). Neurospheres were fixed in ice-cold methanol or in 4% 185 
paraformaldehyde and immunostained with rabbit anti-Nestin (1:200; Chemicon, 186 
Temecula, CA, USA), mouse anti- TuJ1 (1:100; Chemicon), rabbit anti-glial fibrillary 187 
acidic protein (GFAP; 1:500; Chemicon) followed by Alexa fluorophore-conjugated 188 
secondary antibodies (1:100; Molecular Probes, Karlsruhe, Germany).  189 
Furthermore, CD133 and CD15 expression were evaluated by flow cytometry with 190 
anti-CD133/1-Phycoerythrin (PE) or CD133/2-PE antibody and CD15-Viogreen 191 
(Miltenyi Biotec, Bergisch-Gladbach, Germany). CD44, SOX2, Nestin expression and 192 
the amount of cycling cells were evaluated using flow cytometry after staining with 193 
anti-CD44-Alexa700, anti-human SOX2-PE, anti-human Nestin-647 and anti-Ki67-194 
Alexa647 antibodies purchased from BD-Biosciences. Nuclei were counterstained 195 
with 4,6- diamidino-2-phenylindole, DAPI, and 7-aminoactinomycin, 7-AAD.  196 
To assess proliferation cells were incubated for 3-12 h with 10 µM BrdU or EdU at 197 
37°C and 5% CO2. Afterwards the cells were fixed and stained using the BrdU-Flow 198 
and EdU-Flow Kit from BD Biosciences (San Jose, CA, USA). 199 
Cells were analyzed in a BD-FACS Canto II flow cytometer, final data were 200 
processed with the help of FlowJo flow cytometry analysis software. To translate flow 201 
cytometric expression data for statistic evaluation the mean fluorescence value after 202 
staining with the respectively isotype antibody was log-transformed and subtracted 203 
from the log-transformed mean fluorescence value of the specific antibody. This 204 
transformation translates the shift seen when performing overlays in graphically 205 
presented flow data. Values smaller than 0.12 corresponding to a specific 206 
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fluorescence index, SFI, (Hueber et al. 2003) smaller than 1.3 were regarded as no 207 
specific staining for a marker and therefore no marker expression. 208 
 209 
Animal experiments and preparation of mouse brains for histology 210 
All animal work was performed in accordance with the German animal protection law 211 
(Approving institution: Regierungspräsidium Karlsruhe). Tumorigenicity was 212 
determined by injecting 50 to 105 glioblastoma-derived neurosphere cells suspended 213 
in PBS orthotopically into the right striatum of 6-12 weeks old athymic female mice 214 
(CD1 nu/nu, Charles River, Sulzfeld, Germany) by a stereotactic procedure. To 215 
reduce pain animals were anesthetized with xylazine and ketamine. Neurological 216 
symptoms were assessed daily. Symptomatic animals were rapidly sacrificed to 217 
prevent pain. The brains of the sacrificed animals were recultured as described for 218 
the fresh human tumor specimens. Recultured cells were reimplanted at 50-1000 219 
cells after new spheres had formed to assess whether cells could be serially 220 
transplanted. Cryostat transverse brain sections (8 μm) were stained with 221 
hematoxylin-eosin (H&E) or with anti-human Nestin antibody (Chemicon 222 
International, Billerica, USA) and analyzed by AxioVision software (Carl Zeiss, Jena, 223 
Germany). To evaluate the in vivo sensitivity towards irradiation, 2 x 105 GIC were 224 
orthotopically implanted in five animals per group. Seven days later cerebral 225 
irradiation (6 Gy) was performed in the experimental groups. For local irradiation, 226 
brains of nude mice were irradiated using electrons from a standard Linac radiation 227 
source. Positioning and shielding of the animals were achieved by a lead/plastic 228 
device that allows the exact application of the radiation with a 90% isodose to the 229 
targeted 7x 7 mm brain section, sparing the throat of the mice (Tabatabai et al. 230 
2006). 231 
 232 
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TCGA collective 233 
To assess the influence of mRNA expression of defined stem cell markers on 234 
survival in isocitrate dehydrogenase (IDH) wild type patients, methylation (Illumina 235 
HumanMethylation27 BeadChip, n=294 samples and Illumina HumanMethylation450 236 
BeadChip, n=126 samples), mRNA expression (z-score transformed) and clinical 237 
data were obtained from the database of The Cancer Genome Atlas (TCGA, 238 
http://cancergenome.nih.gov) and from cBioPortal (Cerami et al. 2012) at Jan 15 239 
2013. 240 
To detect the gliomas CpG island methylator phenotype (G-CIMP) (and exclude G-241 
CIMP+ patients from further analysis), unsupervised hierarchical clustering of 242 
methylation data was performed as described previously (Wiestler et al. 2013). 243 
Briefly, probes (i) targeting the X and Y chromosomes, (ii) containing a single 244 
nucleotide polymorphism within 5 base pairs of and including the CpG site and (iii) 245 
not mapping uniquely to the human reference genome (hg19), allowing for one 246 
mismatch, were removed. The 1500 (Illumina HumanMethylation27 BeadChip) and 247 
8000 (Illumina HumanMethylation450 BeadChip) most variable (by SD) probes were 248 
kept and unsupervised hierarchical clustering was performed for each platform. 249 
Patients (n = 134) included in this analysis were (i) treatment-naive at the time of 250 
tissue extraction and (ii) initially treated with radio- and chemotherapy 251 
(temozolomide) as in the EORTC-26981-22981 trial (Stupp et al. 2005). Disease-free 252 
survival as reported by the TCGA was the primary endpoint. Statistics: The 253 
assocation of mRNA expression and disease-free survival was assessed through 254 
univariate Cox proprotional hazards regression models. Univariable p values were 255 
adjusted for multiple testing using Benjamini-Hochberg correction in order to control 256 
the false discovery rate (Benjamini Y 1995). Analyses were carried out using R 257 
(Version 3.01) (R Development Core Team 2011). 258 
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 259 
Statistical analysis  260 
Statistical significance was assessed by student’s t-test (Excel, Microsoft, Seattle, 261 
WA, USA) at p<0.05 (significant) or p<0.01 (highly significant). All in vitro 262 
experiments reported here were performed at least two times, flow cytometry data 263 
were repeated at least twice except tumor Ma-1 which stopped growing in cell 264 
culture. For the assessment of a monotonic relationship between the expression 265 
(both on protein and mRNA level) of defined stem cell factors and proliferation & 266 
clonogenicity, Spearman’s rank correlation test was used. 267 
268 
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Results 269 
Glioblastoma-initiating cells  270 
Sphere forming cultures were established from freshly dissected tumor tissue, which 271 
was cultivated after dissociation in neurosphere medium. All GICs formed 272 
neurospheres under this condition (Fig. 1A).  273 
Exposure to serum-containing medium (SCM) for 15 days or BMP-2 in neurosphere 274 
medium (NSCM) without growth factors for 3 days led to differentiation of the sphere 275 
cultures measured by up-regulation of GFAP and the neuronal marker III-tubulin as 276 
shown by immunofluorescence microscopy and flow cytometry for a better 277 
quantification (Fig. 1B-D, Suppl. Fig.1). These differentiation approaches neither 278 
abrogated the expression of the neural stem cell marker Nestin nor the progenitor 279 
and stem cell marker SOX2 as observed before (Gursel et al. 2011). 280 
Cells cultured in neurosphere medium formed orthotopic brain tumors at low cell 281 
numbers. As few as 50 cells / mouse brain were enough to form deeply infiltrating 282 
tumors mimicking the growth pattern of human glioblastomas (Fig. 1E and Suppl. 283 
Fig.1D+E). The time of tumor formation varied from ~90 to more than 200 days in the 284 
different GIC-cultures after implantation of thousand cells (Suppl. Fig.1E). 285 
Interestingly, differentiation in SCM for 15 days did not abrogate tumorigenicity 286 
(Suppl. Fig.1D+E).  287 
Finally, serial repassaging after explantation of the tumors, which had formed in CD1 288 
nu/nu mice, again resulted in gliomas. This detailed analysis was performed for the 289 
GIC-cultures shown in Tab.1. The data presented and the data published before 290 
(Lemke et al. 2012) provide evidence that the cells cultured exhibit stem cell 291 
characteristics.  292 
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Comparative genomic hybridization (CGH) analysis was performed for T1, T325, 293 
T269, WJ, PJ, ZH161, ZH305, KNG002 and S24 and demonstrated the glioblastoma 294 
origin of the GIC-cultures examined (exemplarily in Suppl. Fig.2-4). 295 
 296 
Stem cell marker profiling helped to predict the radiosensitivity of GIC-cultures 297 
in the limiting dilution assay (LDA) 298 
As a high clonogenic potential by itself is supposed to be a characteristic stem cell 299 
feature (Bjerkvig et al. 2005), we performed LDA of 10 different GIC-cultures without 300 
and after irradiation at 4 Gy. The clonogenic potential expressed by one divided by 301 
the amount of cells necessary to form at least one new colony varied from 0.0115 in 302 
tumor MM to 0,88 in S24. In other words, between different GIC cultures 1.1 (S24) to 303 
86 (MM) cells were necessary to form one new colony (Fig.2, upper part). We than 304 
evaluated the radioresistance of the different GIC cultures by dividing the amount of 305 
cells necessary to form at least one colony after irradiation with 4 Gy by the number 306 
of cells necessary without irradiation. In tumor KNG002 it took nearly 80x more cells 307 
after irradiation in the LDA to form at least one new colony while in tumor T325 only 308 
1.5x the amount of cells were necessary (Fig.2, upper part). Tumors with a stronger 309 
reduction of the clonogenic potential after irradiation were regarded as more 310 
radiosensitive compared with the tumors where the difference was smaller. 311 
Interestingly, the clonogenic potential without therapy did not predict sensitivity to 312 
irradiation at 4 Gy.  313 
In a next step, different stem cell markers where profiled in the GIC cultures to 314 
examine whether stem cell marker expression correlates with radioresistance in the 315 
LDA. Flow cytometric expression analysis was performed of the stem cell markers 316 
SOX2, Nestin, CD133, CD15 and CD44 in the ten GIC cultures evaluated in the LDA 317 
before. With the help of Spearman’s rank correlation test we could show that SOX2 318 
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and Nestin expression inversely correlate while CD44 expression positively 319 
correlates with radioresistance in the LDA (p ≥ 0,05) (Fig. 2 lower left). 320 
To gain a broader look on more stem cell markers and assess whether qPCR 321 
analysis suffices to predict radioresistance we further analyzed the mRNA levels of 322 
CD133, Nestin, ALDH1 (Aldehyde dehydrogenase 1), ABCG2 (ATP-binding cassette, 323 
sub-family G member 2), L1CAM (L1 cell adhesion molecule), Musashi1, EZH2 324 
(Enhancer of zeste homolog 2) and PLAGL2 (Pleiomorphic adenoma gene-like 2) in 325 
9 of the GIC cultures examined in the LDA before. 326 
Statistical analysis revealed that CD133, Nestin, Musashi1, PLAGL2 and L1CAM 327 
inversely correlated with radioresistance in the LDA. 328 
 329 
Stem cell marker profiling can help to predict the radiosensitivity of GIC-330 
cultures proliferation 331 
We next evaluated the proliferation rate without and with 4 Gy irradiation of GIC 332 
cultures to examine another parameter, which might reflect radioresistance in vitro. 333 
Therefore, GIC cultures were treated for 6 hours with EdU and incorporation was 334 
measured by flow cytometry (Fig. 3, upper part). During this time tumor MM showed 335 
the weakest EdU-uptake in only ~13 % of the population while tumor PJ had the 336 
strongest proliferation rate with in EdU-uptake in ~41 % of the cells. After irradiation 337 
we could observe a general decline of the proliferation rate. Tumor 325 which was 338 
regarded as a very radioresistant tumor showed a relative proliferation of ~ 94 % 339 
after irradiation while radiosensitive tumors such as T1 and KNG002 went down to 340 
~19 % of their proliferation rate without irradiation. 341 
We did not observe a correlation between proliferation of the unsorted GICs and 342 
increased susceptibility to radiotherapy (Fig. 3; upper part). Aiming again to examine 343 
whether radioresistance in regard to the proliferation rate was predictable by stem 344 
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cell marker profiling, we correlated the relative proliferation rate at 4 Gy with the 345 
expression of the afore mentioned stem cell markers in flow cytometry and qPCR. On 346 
the protein level Nestin inversely correlated with radioresistance (Fig. 3; lower left), 347 
on the mRNA level Musashi1, PLAGL2 and CD133 expression showed an inverse 348 
correlation with radioresistance (Fig. 3; lower right). 349 
 350 
In vitro radiosensitivity correlates with response to radiotherapy in a xenograft 351 
model  352 
Mounting evidence suggests that tumor stem cells occupy a special perivascular and/ 353 
or perinecrotic niche. This niche is supposed to be necessary for GIC to maintain 354 
their stem cell phenotype (Ricci-Vitiani et al. 2010;Seidel et al. 2010;Seoane 355 
2010;Hambardzumyan et al. 2008b). To strengthen the in vitro data on 356 
radiosensitivity, we performed an in vivo experiment allowing the cells to grow in an 357 
orthotopic environment. Exemplarily, T269 which belonged to the group of the 358 
radiosensitive tumors in the LDA and proliferation assay and the radioresistant T325 359 
were implanted each at 2x105 cells in five CD1 nu/nu mice per group. T269-bearing 360 
mice became symptomatic 71 days after implantation. In contrast, animals 361 
orthotopically implanted with T325 cells became symptomatic around day 192. 362 
Interestingly, cranial irradiation with 6 Gy prolonged survival for 36 days in the T269 363 
model, whereas the survival difference between irradiated and untreated animals 364 
implanted with T325 cells was not significant (Fig. 4). We concluded that the in vitro 365 
data were predictive for the in vivo response to irradiation.  366 
 367 
Stem cell marker expression does not correlate with radiochemoresistance in 368 
the TCGA data base 369 
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To translate our data to a larger cohort which better reflects the high genetic 370 
heterogeneity of glioblastoma and its four defined subclasses (Verhaak et al. 2010) 371 
we re-evaluated our results in the TCGA glioblastoma patients collective. The 372 
influence of mRNA expression of the defined stem cell markers on disease-free 373 
survival of radiochemotherapy treated patients with IDH wild-type glioblastomas was 374 
assessed. Methylation, mRNA expression and clinical data were obtained from the 375 
database of The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov) and 376 
from cBioPortal. G-CIMP positive patients were excluded from further analysis to 377 
have a more homogeneous group of primary glioblastomas. Patients (n = 134) 378 
included in this analysis were treatment-naive at the time of tissue extraction and 379 
initially treated with radio- and chemotherapy as in the EORTC 26981/22981 trial 380 
(Stupp et al. 2005). Disease-free survival as reported by the TCGA was the primary 381 
endpoint. This analysis could not demonstrate a correlation between the examined 382 
stem cell markers and survival of the patients (Tab. 2). 383 
 384 
Evaluation of GIC culture subpopulation based on intracellular marker 385 
expression 386 
So far, the experiments performed demonstrated that higher expression of stem cell 387 
markers correlated inversely with radioresistance, with the exception of CD44. Since 388 
glioblastomas are highly heterogeneous tumors and a lot more factors interfere with 389 
radiotherapy such as p53-status and expression of checkpoint kinases, we were 390 
interested to see whether there are subpopulations within a single GIC culture 391 
showing a differential response to radiotherapy. Stem cells are supposed to divide 392 
asymmetrically which should allow identifying different subpopulations within GIC 393 
cultures (Chen et al. 2010;Lathia et al. 2011). Hence, GIC cultures might be 394 
composed of more and less differentiated cells that might be masked by mere 395 
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expression analysis of the whole population. As CD133, CD44 and CD15 were only 396 
be detected in subset of the GIC cultures, we focused on intracellular stem cell 397 
markers. 398 
Therefore, we looked at the expression of Nestin, a marker for neural stem and 399 
progenitor cells (Singh et al. 2004;Strojnik et al. 2007), which correlated inversely 400 
with radioresistance in the LDA and proliferation assay. The GIC cultures tested 401 
showed a monophasic Gaussian distribution of Nestin expression with a 402 
homogeneous BrdU-uptake leading us to the conclusion that cells with a higher 403 
Nestin expression did not proliferate better than low Nestin expressing cells. 404 
Furthermore all the GICs tested were nearly 100% positive for Nestin. Hence, Nestin 405 
did not seem suitable for distinguishing subfractions within individual GIC cultures 406 
(Suppl. Fig. 5). Likewise, the more differentiated astrocytic marker GFAP did not 407 
allow to differentiate subfractions within GIC cultures in vitro (data not shown). 408 
Finally, we examined the expression of the transcription factor SOX2, a progenitor 409 
and stem cell marker, which demonstrated to be central for the tumorigenicity of GIC 410 
cultures. Studies in mice have implicated SOX2 as one of three factors in regulating 411 
pluripotency in embryonic stem cells (Fong et al. 2008;Gangemi et al. 2009;Ikushima 412 
et al. 2009). In contrast to non-neoplastic human astrocytes, SOX2-mRNA was 413 
expressed in GIC cultures (Fig. 5A) and could be detected in glioblastoma tissue 414 
sections (Fig. 5B). Interestingly, on the protein level GIC cultures tested partly formed 415 
subfraction with a SOX2 positive and a SOX2 negative fraction. T269 was nearly 416 
100% positive for SOX2 expression while the SOX2positive fraction was the smallest in 417 
T325 (Fig. 5C). 418 
 419 
The SOX2 subpopulations mainly form the proliferating pool of GIC cultures 420 
and are sensitive to irradiation 421 
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Combining BrdU-incorporation analysis and SOX2-staining in flow cytometry 422 
revealed that SOX2positive –cells better proliferated than SOX2negative-cells.  T269 e.g. 423 
demonstrated a maximal proliferating fraction of 29.5% of cells entering the S-phase 424 
within 6 hours. Of these 29.5 % proliferating cells. 28.8 % were SOX2positive and 0.7% 425 
were SOX2negative (Fig. 5c; left). The SOX2positive fraction formed 95.6% of all cells in 426 
this tumor. T325 was composed of ~ 40 % SOX2positive-cells. Again, the proliferating 427 
cells, 2,49% in this example, were in ~98% SOX2 positive (Fig. 5c; right). 428 
To further characterize the SOX2positive subpopulation, SOX2 and Ki67 were co-429 
stained to assess the cycling cells. Here, ~64% of T325 expressed SOX2. 10.6% of 430 
the SOX2positive cells were cycling detected by a positive Ki67 staining. Only 0,2% of 431 
the 36% SOX2negative cells showed a weak positivity for Ki67 (Fig. 5D). We concluded 432 
that the cycling cells can be almost exclusively found in the SOX2positive fraction. 433 
To finally assess whether SOX2positive cells are sensitive to irradiation, we irradiated 434 
five different GIC cultures with 4 and 8 Gy and analyzed the proliferation capacity 72 435 
h after treatment. All 5 GICs treated showed a dose dependant reduction of the 436 
proliferation rate after irradiation (Fig. 6). T269 e.g. was composed of a nearly 100 % 437 
SOX2positive fraction, of which ~26% took up BrdU within 6 h. After irradiation at 8 Gy 438 
T269 was still composed of nearly 100 % Sox2positive cells but only ~ 6 % were still 439 
proliferating.  440 
The SOX2positive cells which formed predominantly the proliferating pool of the 5 GIC 441 
cultures were, sensitive to irradiation in terms of their proliferation capacity (Fig. 6). 442 
Irradiation did not reduce the amount of SOX2-positive cells 72 h after irradiation. 443 
SOX2negative cells showed also a reduced proliferation rate after irradiation but they 444 
formed only a minority of the proliferating fraction.  445 
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Discussion 446 
The aim of this study was to examine whether markers used to identify cancer stem 447 
cells are of value to predict radiosensitivity in primary glioma cultures obtained from 448 
patient biopsies. We were interested to find out whether profiling of stem cell 449 
characteristics and markers of different GIC cultures or profiling of stem cell markers 450 
within a single GIC culture would allow predicting radiosensitivity of different GIC 451 
cultures or a stem cell subgroup within a single GIC culture. So far cancer stem cells 452 
are regarded highly relevant for recurrence after treatment in glioblastoma patients 453 
(Bao et al. 2006;Beier et al. 2008;Hambardzumyan et al. 2008b;Hambardzumyan et 454 
al. 2008a).  455 
First, we cultivated freshly dissected tumor tissue in neurosphere cell medium until 456 
sphere formation was observed. We performed several experiments demonstrating 457 
that the cultures fulfilled stem cell criteria and were of glioma origin. The GIC-cultures 458 
characterized in detail (Tab.1), formed tumors in low cell numbers, showed a 459 
multilineage differentiation capacity, were propagated in culture for many passages 460 
(except tumor Ma-1) and demonstrated a high clonogenic potential. Surprisingly, 461 
differentiation in serum-containing medium without growth factor supplementation did 462 
not abrogate the expression of the stem cell markers Nestin and SOX2 (Fig. 1, Supl, 463 
Fig. 1) nor the tumorigenic potential in several tumors (Suppl. Fig.1). We did not 464 
examine systematically whether the growth pattern, like the capacity to infiltrate, 465 
changed after the differentiation approach. The fact that tumors still formed argued 466 
against a terminal differentiation by the strategies applied. Similarly, Jiang et al. 467 
published in an experimental glioma model in neonatal Gtv-a Arf(-/-) mice induced by 468 
platelet-derived growth factor-B (PDGF-B) (Jiang et al. 2011) a lingering 469 
tumorigenicity of their sphere cultures after induction of differentiation with FBS. The 470 
authors interpreted that this was due to the high plasticity of their GIC-cultures. 471 
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We next characterized the clonogenic potential in ten GIC cultures with the LDA (Fig. 472 
2). A high clonogenic potential of the unsorted GICs was not associated with a higher 473 
radioresistance in the LDA. We concluded that clonogenicity which by itself is related 474 
to stemness (Bjerkvig et al. 2005) does not allow to predict radioresistance.  475 
However, the relative reduction of the clonogenicity may be used as a parameter for 476 
radioresistance allowing comparing the different GIC cultures examined. As a second 477 
parameter to evaluate radioresistance, we determined the relative decline of the 478 
proliferation rate 72 h after irradiation with 4 Gy measured bei EdU incorporation. 479 
Correlating radioresistance in the LDA and proliferation assay with the protein 480 
expression of the stem cell markers CD133, CD15, CD44, Nestin and SOX2 as well 481 
as the mRNA levels of Nestin, Musashi1, L1Cam, ABCG2, ALDH1, CD133, PLAGL2 482 
and EZH2 revealed an unexspected result. Only CD44 protein expression correlated 483 
with radioresistance in the LDA, while Nestin and SOX2 protein expression as well as 484 
Nestin, L1CAM, Musashi1, PLAGL2 and CD133 mRNA levels correlated inversely 485 
with radioresistance in the LDA. The proliferation analysis showed a negative 486 
correlation for radioresistance and Nestin protein expression as well as Musashi1, 487 
PLAGL2 and CD133 mRNA-levels. The absolute proliferation rate of the different 488 
GIC cultures without irradiation was not predictive for radiotherapy sensitivity. We 489 
concluded that there is no trivial association between irradiation effects and 490 
proliferation.  491 
These unexpected results are in line with data published before by Beier et al. (Beier 492 
et al. 2008) who examined chemotherapy sensitivity in CD133 positive and negative 493 
cancer stem cell cultures. CD133 was originally suggested to be a key marker for 494 
GIC growing as spheroids (Lottaz et al. 2010;Singh et al. 2003;Singh et al. 2004). It 495 
is expressed in neural stem cells and has been attributed a role in the development 496 
of the central nervous system (Uchida et al. 2000). After the initial paper by Singh et 497 
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al. (Singh et al. 2003) several studies have identified stem cells by their expression of 498 
CD133. CD133 and related CD133positive cells were associated with a phenotype of 499 
resistance towards radiotherapy (Bao et al. 2006;Rich 2007). Anyway, in the 500 
publication from Beier et al. CD133 negative cells were associated with 501 
chemoresistance. This is in line with a growing number of publications showing 502 
glioma initiation by CD133negative cells that even gave rise to CD133positive cells (Chen 503 
et al. 2010;Lee et al. 2006b;Wang et al. 2008) calling the importance of CD133 as a 504 
stem cell marker in question.  505 
Our in vitro results, which allow predicting radiotherapy sensitivity, were strengthened 506 
by the in vivo experiment. Tumor T269, in vitro classified as a more radiosensitive 507 
tumor than T325, proved to be also more radiosensitive in orthotopic xenotranplanted 508 
nude mice treated at 6 Gy (Fig. 4). 509 
Hence, the microenvironment, which is provided in the mouse, did not alter the 510 
differential in vitro radiosensitivity of the GIC lines. Considering that GICs are 511 
supposed to differentiate into endothelial cells and vessel like structures (Ricci-Vitiani 512 
et al. 2010) one should assume that GICs are capable to create their niche to some 513 
extent in the mouse brain. Therefore, we concluded that radiosensitivity measured in 514 
vitro by LDA and proliferation analysis mirrors the sensitivity of our GIC lines 515 
realistically and is more than an in vitro artefact. Although it is unclear whether cells 516 
implanted 7 days before irradiation as scheduled in the experiment are capable to 517 
establish an own niche for the stem cells. At least, the in vivo experiment which 518 
covers a time frame from more than 200 days underlined that the irradiation effects 519 
measured after 72h in vitro reflect more than a casual snap-shot. 520 
To argue against a too small number of GIC cultures tested (n=10) we tried to 521 
translate our concept into a clinical context by correlating the mRNA level of 522 
accepted stem cell markers in a TCGA glioblastoma collective with their sensitivity to 523 
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radiochemotherapy measured by disease-free survival. Here, no stem cell marker 524 
tested predicted resistance or sensitivity to therapy (Tab. 2). There are several 525 
possible explanations for this lack of translation. The data in the TCGA are generated 526 
by tumor and bystander cells in an unknown ratio and in vitro culturing of GICs by 527 
itself is prone to amplify subtypes of glioblastomas (Laks et al. 2009). Thus, our 528 
experimental findings were not strengthened by this analysis. Yet, the widely 529 
accepted stem cell concept arguing that stem cell marker defined cells are more 530 
resistant and therefore the basis for recurrent disease was also not supported. An 531 
example for a more robust concept for bona fide stem cells might be given by stem 532 
cells driven by the nuclear receptor tailless (Tlx) (Zhu et al. 2014).   533 
Finally, as glioblastomas are supposed to be hierarchically organized and stem cells 534 
divide asymmetrically, we established a multiparameter flow cytometric approach to 535 
examine cell cycle distribution and proliferation rate in different subfractions within a 536 
single GIC culture. We focussed on the intracellular markers Nestin and SOX2 trying 537 
to detect more radioresistant CSC subfractions. Nestin was not suitable to detect 538 
subpopulation in vitro within different GIC cultures since its expression was 539 
distributed evenly and all the GIC cultures tested were nearly 100% positive for 540 
Nestin (Suppl. Fig. 5). SOX2, on the other hand, differentiated subfractions within the 541 
GIC cultures tested. The amount of SOX2positive cells varied from more than 95% to 542 
~17% (Fig. 6). SOX2positive cells almost exclusively expressed Ki67, which is a marker 543 
for cycling cells (Fig. 5D). But most importantly, the SOX2positive proliferating 544 
subpopulation was sensitive to irradiation (Fig. 6). This was finally not surprising as 545 
we could demonstrate that the SOX2positive cells formed mainly the proliferating 546 
fraction of the cells. Irradiation did not hamper SOX2 expression itself within the first 547 
72 hours after irradiation but clearly reduced the amount of proliferating cells in five 548 
different GIC cultures within this subfraction. 549 
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These results explain why silencing of SOX2 attenuates tumorigenicity (Gangemi et 550 
al. 2009) and is in line with the assumption that SOX2 cooperates with cylin D1 in cell 551 
cycle progression (Oppel et al. 2011).  552 
The only positive correlation between stem cell marker expression and 553 
radioresistance was detected for CD44 which is in line with published data showing 554 
that CD44 promotes tumor cell resistance to reactive oxygen species-induced and 555 
cytotoxic agent-induced stress by attenuating activation of the Hippo signalling 556 
pathway (Xu et al. 2010). 557 
To conclude, within the last decade the cancer stem cell concept has gained a lot of 558 
attention in the glioma field. Many markers and techniques have been published to 559 
detect the cancer stem cells within glioma samples. We tested some of these 560 
markers and techniques to prove whether they are valuable to predict resistance to 561 
radiotherapy, a feature, which is attributed to cancer stem cells. Our profiling 562 
strategies revealed that the majority of the significantly correlating stem cell markers 563 
tested show an inverse correlation with radioresistance except CD44. Kim et al. 564 
came to a similar result when profiling samples of different radiochemotherapy 565 
treated glioblastoma patients for CD133, CD15 and Nestin expression which did not 566 
correlate with a better survival (Kim et al. 2011). Furthermore, SOX2 emerged to be a 567 
marker useful to detect subfractions within single GIC cultures composing 568 
predominantly the cycling and radiosensitive cells in our hands.  569 
It is likely that cancer stem cells are not sufficiently characterized by single markers. 570 
It is also likely that surface markers in solid tumors, analyzed after dissociation of the 571 
tumor, do not represent a biology-related phenotype, but are prone to change by the 572 
manipulation, may shift over time or in response to the microenvironment. 573 
Considering further that we have achieved in only around 30-50% of all the patient-574 
derived tissue to establish a GIC culture it might well be that the in vitro data are 575 
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simply not appropriate to mirror the in vivo conditions. But taking all this limitations 576 
into account and being aware of the fact that tumor stem cells derived from 577 
glioblastomas cultured in bFGF and EGF are probably the best in vitro model we 578 
have (Lee et al. 2006a) these data call the widely accepted theory that stem cells are 579 
the source of therapy resistance in question. At least the markers published to detect 580 
stem cells should not be used without scepticism. Finally, our data point at further 581 
evaluating the role and therapeutic options of CD44 in radioresistance of 582 
glioblastomas. 583 
584 
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Figure legends 807 
Fig. 1: GIC cultures fulfill the stem cell characteristics sphere formation, 808 
multilineage differentiation and tumorigenicity 809 
A: GIC cultures T325 and T269 form neurospheres in NSCM. 810 
B: T269 cultured in SCM, serum-containing medium (T269S) and NSCM, 811 
neurosphere cell medium (T269). T269S shows upregulation of GFAP- and III-812 
tubulin expression, Nestin stays positive after induction of differentiation for 15 days 813 
in serum containing medium. 814 
C: Differentiation can also be induced in T269 with bone morphogenic protein-2 815 
(BMP-2) treatment for 72 h in NSCM devoid of EGF and FGF. (III)-tubulin 816 
expression (Tuj1) was quantified by flow cytometry. It is induced after treatment with 817 
BMP-2 (dotted line: isotype-antibody; dense line: Tuj1-antibody, vertical dash: mean 818 
Tuj-1 expression of the undifferentiated NSCM-cultured cells,  819 
D: BMP-2 can also induce the expression of the glial marker GFAP but does not 820 
reduce the expression of the stem cell markers Nestin and SOX2. Percentage of 821 
marker positive cells was quantified. 822 
E: Tumor formation of T269 in nude mouse brain. Anti-human Nestin antibody 823 
(green) illustrates the infiltrative growth. Nuclei are counterstained with DAPI. Higher 824 
magnification in the lower panels of E demonstrate that T269 infiltrates far into the 825 
contralateral hemisphere. 826 
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Fig. 2: Stem cell marker expression correlates with radioresistance measured 
in the limiting dilution assay (LDA) 
Upper part: Clonogenicity of 10 different GIC cultures is presented as 1/divided by 
the amount of cells necessary to form at least on new colony (small square points, 
black lines represent the standard error of the mean calculated by L-Calc;  
STEMCELL technologies). Bars represent the relative clonogenicity after irradiation 
with 4 Gy calculated by dividing the amount of cells necessary to form one new 
colony at 0 Gy from the number at 4 Gy. High results represent more sensitive 
tumors. GICs were sorted along their radiosensitivity and colour coded. The most 
sensitive tumors are on the left side visualized in dark green, while the most resistant 
tumor can be found at the right side in dark red. 
Lower part:   The same 10 GIC cultures were analyzed for the expression of the 
signified stem cell markers by flow cytometry (left part) and 9 of the 10 GICs were 
further evaluated for the mRNA expression of several stem cell markers (right). The 
colours from dark green to dark right mirror the sensitivity to radiotherapy visualized 
in the upper part of the figure. Stars symbolize a significant inverse or positive 
correlation between a stem cell marker and radioresistance (p ≥ 0,05).    
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Fig. 3: Stem cell marker expression correlates with radioresistance measured 
by proliferation 
Upper part: The proliferation rate of 10 different GIC cultures is presented as the 
percentage of cells incorporating EdU within a pulse experiment of 6 h (small square 
points, black lines represent the standard deviation). Bars represent the relative 
proliferation rate in percent after irradiation at 4 Gy calculated by dividing the 
proliferating cells at 0 Gy from the number at 4 Gy. High results represent more 
resistant tumors. GICs were sorted along their radiosensitivity and colour coded. The 
most sensitive tumors are on the left side visualized in dark green, while the most 
resistant tumor can be found at the right side in dark red. 
Lower part:   The same 10 GIC cultures were analyzed for the expression of the 
signified stem cell markers by flow cytometry (left part) and 9 of the 10 GICs were 
further evaluated for the mRNA expression of several stem cell markers (right). The 
colours from dark green to dark right mirror the sensitivity to radiotherapy visualized 
in the upper part of the figure. Stars symbolize a significant inverse or positive 
correlation between a stem cell marker and radioresistance (p ≥ 0,05).    
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Fig. 4: In vivo response to irradiation in orthotopically grown GIC tumors 
underlines that T269 is more radiosensitive than T325  
Kaplan-Meier survival analysis was performed for mice orthotopically implanted with 
2*105 T269 or T325 cells (n=5) irradiated in situ (day 7 after implantation) at 6 Gy or 
not. Irradiation has only a significant therapeutic effect on mice implanted with T269 
which survive approximately 36 days ~ 50%) longer. Mice implanted with T325 did 
not show a significant survival benefit. 
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Fig. 5: SOX2psositive and negative subpopulations exist in GIC cultures 
A: quantitative RT-PCR demonstrates that GIC cultures express higher levels of 
SOX2 than human astrocytes (hAS) (*: p< 0,05; **: p<0,01). 
B: SOX2-staining of PFA-fixed human glioblastoma sample 1462 shows that tumor 
cells are heterogeneously positive for SOX2. Endothelial cells stained by CD31 do 
not express SOX2. Nuclei are counterstained with DAPI. 
C: SOX2positive cells form mainly the proliferating fraction of the GIC cultures T269, T1 
and T325. The histogram was overlayed with the dot blot of T269 (left panel) to 
demonstrate how SOX2positive and negative cells were gated (dashed line: isotype stained 
cells; dense line: SOX2 stained cells). SOX2 expression on the x-axis was plotted 
against BrdU-incorporation on the y-axis. Cells we treated for 6 h with BrdU. 
D: SOX2positive cells form almost exclusively the Ki67positive cycling pool of T325. 
Double staining with Ki67 and SOX2 in flow cytometry demonstrates that practically 
all the cycling Ki67 positive cells belong to the SOX2positive fraction (10.6%) while only 
0.2% of the cycling cells are SOX2negative. 
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Fig. 6: SOX2positive cells form predominantly the proliferating pool of GIC 
cultures and are sensitive to irradiation  
5 GIC cultures (T269, T325, T1, Ma-1, H1) were irradiated with 4 and 8 Gy in vitro. 
After 72h proliferation was measured by BrdU uptake for 6 h (y-axis) in the GIC 
cultures and plotted against SOX2 expression (x-axis) to allow differentiation 
between more stem cell related SOX2positive cells and the SOX2negative cells within one 
single GIC culture. All the GIC show a dose dependant decline of their proliferation 
rate after irradiation. The SOX2positive cells, which formed predominantly the 
proliferating cells (control) are sensitive to irradiation. Irradiation does not lead 
uniformly to a change of the size of the SOX2 positive population 72 h after therapy. 
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Tab. 1: Comparison of GIC cultures T269, T1, T325 and Ma-1 in regard to established stem cell marker expression and 
functional stem cell characteristics 
 
 
 
Comparison of tumorigenicity after orthotopic implantation of 103 cells, aggressiveness of tumor growth (assessed by the interval, in 
which the animals got symptomatic), infiltration and in vivo passaging capacity of tumor cells, multilineage differentiation and long-term 
cell culture, describing the capacity of a sphere culture to be passaged for more than ten times. The expression of SOX2, Nestin and 
CD133 was analyzed by flow cytometry. Tumor Ma-1, which grew very aggressively in vivo stopped proliferating in vitro.  Hence, Ma-1 
did not fulfil all cancer stem cell criteria (n.p.=not possible). (Stronger infiltration with tumor cells reaching the contralateral hemisphere 
was marked with ++). 
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Tab. 2: Stem cell marker expression does not correlate with radiochemo-
resistance in a TCGA collective 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stem cell marker mRNA expression of a TCGA collective of radiochemotherapy 
treated glioblastoma Patients (n=134) was correlated with the risk (Hazard Ratio, HR) 
to have a shorter disease-free survival. No marker shows a significant influence on 
disease-free survival after treatment (CI: Confidence interval, p: level of significance). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gen HR 95% CI p
ABCG2 0,946 0,7328‐1,22 0,963
ALDH1A1 0,893 0,7064‐1,128 0,963
BMI1 0,962 0,7488‐1,236 0,977
EZH2 0,884 0,7081‐1,104 0,963
Integrin6 1,051 0,8408‐1,315 0,963
KLF4 1,087 0,8901‐1,328 0,963
Musashi1 0,835 0,5194‐1,343 0,963
NANOG 0,997 0,8051‐1,234 0,977
NESTIN 1,227 0,9185‐1,638 0,963
OLIG2 0,948 0,7819‐1,149 0,963
PLAGL2 1,091 0,9012‐1,321 0,963
Oct4 1,013 0,8073‐1,272 0,977
CD133 0,977 0,793‐1,204 0,977
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Supplemental Fig. 1:
A: GIC-tumor T269 is multipotent.
Flow cytometric analysis of differentiated markers, GFAP and III-tubulin, as well as the stem
cell markers musashi-1, SOX2 and Nestin after induction of differentiation with CNTF, BMP2
(at concentrations of 10 and 50 ng/ml) for 3 days with and without the use of 5-azacytidine or
pure growth factor withdrawal. Expression is compared to T269 kept in NSCM. Isotype
stainings show that marker staining was specific. GFAP and III-tubulin are upregulated to a
various degree depending on differentiation approach. Differentiation approaches do not lower
the expression of the stem cell markers examined (dashed line helps to estimate the
expression level of the isotype).
B+C: T325 shows multilineage differentiation capacity but cannot be terminally
differentiated with the help of serum-containing medium (SCM).
Upper panel:
T325 forms neurospheres in NSCM and shows expression of Nestin and GFAP in
immunocytochemistry.
Lower panel:
Differentiation with SCM for 15 (T325S) days leads to formation of a monolayer in T325 with
upregulation of GFAP and -III-tubulin expression in immunocytochemistry. Nestin expression is
still positive after differentiation with SCM.
C: Quantification of GFAP and Nestin expression by flow cytometry demonstrates that
differentiation of T325 (T325S) for 15 days in SCM reduces Nestin expression only marginally
and leads to upregulation of GFAP in some cells. (dotted line: isotype; black (undifferentiated)
and grey (differentiated) line: specific staining for Nestin and GFAP.
D+E: Tumors T325, T269 and T1 are highly tumorigenic.
D: Immunofluorescence microscopy against anti-human Nestin and HE (hematoxylin eosin)
stainings show that T1, T325 and T269 form tumors in nude mice when kept in NSCM but also
after induction of differentiation in SCM for 15 days (T325S, T269S, T1S). Nestin staining
shows that cells infiltrate into the surrounding brain.
E: Tumors T325, T269 and T1 form tumors after implantation of only 1000 GIC-culture cells
(bars with dotted lines). Generation time of tumors varies from ~90 to more than 200 days in
the different GIC-cultures and is faster after implantation of 50.000 cells (bars with dense
lines).
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Supplemental Fig. 2-4:
CGH-analysis (comparative genomic hybridization) of the GIC cultures T325, T1 and T269
underline the glioblastoma origin of the GICs. Losses and gains are visualized and plotted
against their origin on the different chromosomes.
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Supplemental Fig. 5
Supplemental Fig. 5:
BrdU-uptake was plotted against Nestin expression in 4 different GIC cultures (right side).
Cells take up BrdU homogeneously, subfractions with a distinct Nestin expression or
proliferation rate can not be detected). Histogramms on the left side show that all the
cultures tested are 100 % positive for Nestin and that this marker is normally distributed in
the different GIC cultures (black line shows the expression of Nestin, grey line shows
isotype expression). Cells were treated for 6 hours with BrdU.
